Breast Cancer

Scalp cooler prevents hair loss in early stage breast cancer patients

A pioneering scalp cooling treatment that prevents alopecia in early stage breast cancer patients undergoing chemotherapy will be showcased at the 15th St. Gallen International Breast Cancer Conference, Vienna.

Paxman Scalp Cooling System
Paxman Scalp Cooling System
Source: Paxman

Throughout the four-day exhibition, which runs from 15-18th March, British company Paxman will showcase the Paxman Hair Loss Prevention System, an innovative device that prevents women from losing their hair whilst undergoing chemotherapy.

The device operates using a two-cap system, with the inner silicone cap circulating a refrigerated fluid and the outer neoprene cap insulating the scalp and fitting snugly to the patient’s head with a chin strap.

Both caps are fitted once and worn for the duration of each chemotherapy treatment session. The two-cap system ensures the coolant stays at a consistent temperature and is connected to a small machine, which can be briefly detached from the patient to allow for greater mobility during sessions.

Dr Julie Nangia recently used the scalp cooler in her Scalp Cooling Alopecia Prevention trial (SCALP) at Baylor College of Medicine in the United States.

The study highlighted that the scalp cooler is highly effective in hair preservation after the fourth chemotherapy cycle for patients who receive taxane or anthracycline, or both, during chemotherapy for stage I or II breast cancer.

The impressive results of the trial were recently featured in JAMA; a renowned peer-reviewed oncology medical journal published by the American Medical Association.

Dr Nangia said: “Chemotherapy treatment works by attacking rapidly dividing cells, but in doing this, it also targets rapidly-dividing hair cells, 90 percent of which are in the growth stage, resulting in hair loss.”

“With scalp cooling, we are lowering the temperature of the scalp, thereby constricting the blood vessels and reducing the flow of blood to the hair follicles, which will help reduce hair loss by limiting the amount of chemo drugs reaching the follicles.”

Richard Paxman, CEO at Paxman, said: “We are looking forward to coming to St. Gallen International Breast Cancer Conference to highlight the SCALP clinical trial results. We have had some great clinical results around the world, especially in the US, so it’s great to be able to share these results with clinicians at international conferences.”

Throughout the conference the Paxman Hair Loss Prevention System device will be located on Stand 3, Level 0 The Austria Centre, Vienna.

For more information please visit:

Paxman Coolers Limited
International House
Penistone Road
Fenay Bridge
West Yorkshire
Tel: +44(0)1484 349 444

Source: press release Paxman


Read all latest stories

Related articles


DNA damage causes AML

Cancer chemotherapy side-effects on blood cell development

By analysing secondary acute myeloid leukaemias, researchers at the Institute for Research in Biomedicine (IRB) Barcelona have detected mutations caused by platinum-based chemotherapies in cells that…


Mammacarcinoma study

Breast cancer: finishing treatment soon after diagnosis increases survival

Research from Cleveland Clinic in the U.S. and Cleveland Clinic Abu Dhabi in the U.A.E. has found a decrease in patient survival rates when treatment options – surgery, chemotherapy and radiation…


Oestrogen-receptor positive, HER2-negative

Test determines most effective treatment for breast cancer

A breast cancer test has been found that helps doctors make treatment decisions for some breast cancer patients, following research carried out at Queen Mary University of London and funded by Cancer…

Related products

Hologic - I-View 2.0 Contrast Enhanced Imaging

Mammo Workstations

Hologic - I-View 2.0 Contrast Enhanced Imaging

Hologic, Inc.
Hologic - LOCalizer wire-free guidance system

Accessories / Complementary Systems

Hologic - LOCalizer wire-free guidance system

Hologic, Inc.
iCAD - Profound AI Risk

Artificial Intelligence

iCAD - Profound AI Risk

Therapixel · MammoScreen

Artificial Intelligence

Therapixel · MammoScreen